메뉴 건너뛰기




Volumn 87, Issue 1, 2013, Pages 41-54

Bevacizumab in older patients with advanced colorectal or breast cancer

Author keywords

Bevacizumab; Breast cancer; Colorectal cancer; Elderly

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB;

EID: 84878570619     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.11.006     Document Type: Review
Times cited : (8)

References (109)
  • 2
    • 0030886129 scopus 로고    scopus 로고
    • Cancer burden in the aged: an epidemiologic and demographic overview
    • October
    • Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997, 80(October (7)):1273-1283.
    • (1997) Cancer , vol.80 , Issue.7 , pp. 1273-1283
    • Yancik, R.1
  • 3
    • 67649993396 scopus 로고    scopus 로고
    • Future of cancer incidence in the United States: burdens upon an aging, changing nation
    • June
    • Smith B.D., Smith G.L., Hurria A., Hortobagyi G.N., Buchholz T.A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. Journal of Clinical Oncology 2009, 27(June (17)):2758-2765.
    • (2009) Journal of Clinical Oncology , vol.27 , Issue.17 , pp. 2758-2765
    • Smith, B.D.1    Smith, G.L.2    Hurria, A.3    Hortobagyi, G.N.4    Buchholz, T.A.5
  • 4
    • 77953619300 scopus 로고    scopus 로고
    • The treatment of co-morbidities in older patients with metastatic cancer
    • May
    • Cashman J., Wright J., Ring A. The treatment of co-morbidities in older patients with metastatic cancer. Supportive Care in Cancer 2010, 18(May (5)):651-655.
    • (2010) Supportive Care in Cancer , vol.18 , Issue.5 , pp. 651-655
    • Cashman, J.1    Wright, J.2    Ring, A.3
  • 5
    • 0035846327 scopus 로고    scopus 로고
    • Older age - not a barrier to cancer treatment
    • October
    • Muss H.B. Older age - not a barrier to cancer treatment. New England Journal of Medicine 2001, 345(October (15)):1127-1128.
    • (2001) New England Journal of Medicine , vol.345 , Issue.15 , pp. 1127-1128
    • Muss, H.B.1
  • 6
    • 79958043675 scopus 로고    scopus 로고
    • National Cancer stitute, Bethesda, MD, (based on November 2011 SEER data submission, posted to the SEER web site, April)
    • Howlader N., Noone A.M., Krapcho M., et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) 2012, National Cancer Institute, Bethesda, MD, (based on November 2011 SEER data submission, posted to the SEER web site, April). http://seer.cancer.gov/csr/1975_2009_pops09/.
    • (2012) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations)
    • Howlader, N.1    Noone, A.M.2    Krapcho, M.3
  • 7
    • 83355174078 scopus 로고    scopus 로고
    • Improvement in breast cancer outcomes over time: are older women missing out?
    • Smith B.D., Jiang J., McLaughlin S.S., et al. Improvement in breast cancer outcomes over time: are older women missing out?. Journal of Clinical Oncology 2011, 29(35):4647-4653.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.35 , pp. 4647-4653
    • Smith, B.D.1    Jiang, J.2    McLaughlin, S.S.3
  • 8
    • 83355166958 scopus 로고    scopus 로고
    • Older women with breast cancer: slow progress, great opportunity, now is the time
    • Muss H.B., Busby-Whitehead J. Older women with breast cancer: slow progress, great opportunity, now is the time. Journal of Clinical Oncology 2011, 29(35):4608-4610.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.35 , pp. 4608-4610
    • Muss, H.B.1    Busby-Whitehead, J.2
  • 10
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • December
    • Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. New England Journal of Medicine 2007, 357(December (26)):2666-2676.
    • (2007) New England Journal of Medicine , vol.357 , Issue.26 , pp. 2666-2676
    • Miller, K.1    Wang, M.2    Gralow, J.3
  • 11
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • June
    • Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004, 350(June (23)):2335-2342.
    • (2004) New England Journal of Medicine , vol.350 , Issue.23 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 12
    • 34248173883 scopus 로고    scopus 로고
    • Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200
    • April
    • Giantonio B.J., Catalano P.J., Meropol N.J., et al. Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. Journal of Clinical Oncology 2007, 25(April (12)):1539-1544.
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.12 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3
  • 13
    • 79952284127 scopus 로고    scopus 로고
    • Hallmarks of cancer: the next generation
    • March
    • Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(March (5)):646-674.
    • (2011) Cell , vol.144 , Issue.5 , pp. 646-674
    • Hanahan, D.1    Weinberg, R.A.2
  • 14
    • 1842830358 scopus 로고    scopus 로고
    • Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels
    • April
    • Baffert F., Thurston G., Rochon-Duck M., Le T., Brekken R., McDonald D.M. Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. Circulation Research 2004, 94(April (7)):984-992.
    • (2004) Circulation Research , vol.94 , Issue.7 , pp. 984-992
    • Baffert, F.1    Thurston, G.2    Rochon-Duck, M.3    Le, T.4    Brekken, R.5    McDonald, D.M.6
  • 17
    • 0038376002 scopus 로고    scopus 로고
    • Molecular regulation of vessel maturation
    • June
    • Jain R.K. Molecular regulation of vessel maturation. Nature Medicine 2003, 9(June (6)):685-693.
    • (2003) Nature Medicine , vol.9 , Issue.6 , pp. 685-693
    • Jain, R.K.1
  • 18
    • 0034076189 scopus 로고    scopus 로고
    • Mechanisms of angiogenesis and arteriogenesis
    • April
    • Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Medicine 2000, 6(April (4)):389-395.
    • (2000) Nature Medicine , vol.6 , Issue.4 , pp. 389-395
    • Carmeliet, P.1
  • 19
    • 0029761644 scopus 로고    scopus 로고
    • Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
    • September
    • Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and Cellular Biology 1996, 16(September (9)):4604-4613.
    • (1996) Molecular and Cellular Biology , vol.16 , Issue.9 , pp. 4604-4613
    • Forsythe, J.A.1    Jiang, B.H.2    Iyer, N.V.3
  • 21
    • 84878550755 scopus 로고    scopus 로고
    • Genentech, c., United States Securities and Exchange Commission. [accessed 04.05.12]
    • Genentech, Inc., United States Securities and Exchange Commission. [accessed 04.05.12]. http://www.sec.gov/Archives/edgar/data/318771/000031877109000003/form10-k_2008.htm.
  • 22
    • 0034796595 scopus 로고    scopus 로고
    • Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy
    • September
    • Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nature Medicine 2001, 7(September (9)):987-989.
    • (2001) Nature Medicine , vol.7 , Issue.9 , pp. 987-989
    • Jain, R.K.1
  • 23
    • 20044375603 scopus 로고    scopus 로고
    • Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
    • Wang Y., Fei D., Vanderlaan M., Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7(4):335-345.
    • (2004) Angiogenesis , vol.7 , Issue.4 , pp. 335-345
    • Wang, Y.1    Fei, D.2    Vanderlaan, M.3    Song, A.4
  • 24
    • 8844276697 scopus 로고    scopus 로고
    • Translating angiogenesis research into the clinic: the challenges ahead
    • Spec No 1, S3-S10
    • Augustin H.G. Translating angiogenesis research into the clinic: the challenges ahead. British Journal of Radiology 2003, 76. Spec No 1, S3-S10.
    • (2003) British Journal of Radiology , vol.76
    • Augustin, H.G.1
  • 25
    • 34447329590 scopus 로고    scopus 로고
    • Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors
    • July
    • Homsi J., Daud A.I. Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control Journal of the Moffitt Cancer Center 2007, 14(July (3)):285-294.
    • (2007) Cancer Control Journal of the Moffitt Cancer Center , vol.14 , Issue.3 , pp. 285-294
    • Homsi, J.1    Daud, A.I.2
  • 26
    • 84863092492 scopus 로고    scopus 로고
    • VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
    • July
    • Lambrechts D., Claes B., Delmar P., et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncology 2012, 13(July (7)):724-733.
    • (2012) Lancet Oncology , vol.13 , Issue.7 , pp. 724-733
    • Lambrechts, D.1    Claes, B.2    Delmar, P.3
  • 27
    • 62949129110 scopus 로고    scopus 로고
    • Intricacies of bevacizumab-induced toxicities and their management
    • March
    • Gressett S.M., Shah S.R. Intricacies of bevacizumab-induced toxicities and their management. Annals of Pharmacotherapy 2009, 43(March (3)):490-501.
    • (2009) Annals of Pharmacotherapy , vol.43 , Issue.3 , pp. 490-501
    • Gressett, S.M.1    Shah, S.R.2
  • 28
    • 0026081916 scopus 로고
    • The renal lesion of preeclampsia revisited
    • February
    • Kincaid-Smith P. The renal lesion of preeclampsia revisited. American Journal of Kidney Diseases 1991, 17(February (2)):144-148.
    • (1991) American Journal of Kidney Diseases , vol.17 , Issue.2 , pp. 144-148
    • Kincaid-Smith, P.1
  • 29
    • 0031471950 scopus 로고    scopus 로고
    • Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium
    • November
    • Horowitz J.R., Rivard A., van der Zee R., et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arteriosclerosis Thrombosis and Vascular Biology 1997, 17(November (11)):2793-2800.
    • (1997) Arteriosclerosis Thrombosis and Vascular Biology , vol.17 , Issue.11 , pp. 2793-2800
    • Horowitz, J.R.1    Rivard, A.2    van der Zee, R.3
  • 30
    • 78649978359 scopus 로고    scopus 로고
    • Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials
    • Geiger-Gritsch S., Stollenwerk B., Miksad R., Guba B., Wild C., Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010, 15(11):1179-1191.
    • (2010) Oncologist , vol.15 , Issue.11 , pp. 1179-1191
    • Geiger-Gritsch, S.1    Stollenwerk, B.2    Miksad, R.3    Guba, B.4    Wild, C.5    Siebert, U.6
  • 31
    • 79955845678 scopus 로고    scopus 로고
    • Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials
    • May
    • Cuppone F., Bria E., Vaccaro V., et al. Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: meta-regression analysis of randomized trials. Journal of Experimental & Clinical Cancer Research 2011, 30(May):54.
    • (2011) Journal of Experimental & Clinical Cancer Research , vol.30 , pp. 54
    • Cuppone, F.1    Bria, E.2    Vaccaro, V.3
  • 32
    • 80053200932 scopus 로고    scopus 로고
    • An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity
    • Mir O., Coriat R., Cabanes L., et al. An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity. Oncologist 2011, 16(9):1325-1332.
    • (2011) Oncologist , vol.16 , Issue.9 , pp. 1325-1332
    • Mir, O.1    Coriat, R.2    Cabanes, L.3
  • 33
    • 60549118166 scopus 로고    scopus 로고
    • Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
    • February
    • Scartozzi M., Galizia E., Chiorrini S., et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Annals of Oncology 2009, 20(February (2)):227-230.
    • (2009) Annals of Oncology , vol.20 , Issue.2 , pp. 227-230
    • Scartozzi, M.1    Galizia, E.2    Chiorrini, S.3
  • 34
    • 53749093040 scopus 로고    scopus 로고
    • ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
    • October
    • Schneider B.P., Wang M., Radovich M., et al. ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. Journal of Clinical Oncology 2008, 26(October (28)):4672-4678.
    • (2008) Journal of Clinical Oncology , vol.26 , Issue.28 , pp. 4672-4678
    • Schneider, B.P.1    Wang, M.2    Radovich, M.3
  • 35
    • 79959426381 scopus 로고    scopus 로고
    • Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers
    • Escalante C.P., Zalpour A. Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. Cardiology Research and Practice 2011, 2011:816897.
    • (2011) Cardiology Research and Practice , vol.2011 , pp. 816897
    • Escalante, C.P.1    Zalpour, A.2
  • 36
    • 33845656482 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension
    • December
    • Dincer M., Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Annals of Pharmacotherapy 2006, 40(December (12)):2278-2279.
    • (2006) Annals of Pharmacotherapy , vol.40 , Issue.12 , pp. 2278-2279
    • Dincer, M.1    Altundag, K.2
  • 37
    • 62949116808 scopus 로고    scopus 로고
    • Bevacizumab related adverse events among various age groups of elderly patients with advanced colorectal cancer (abstract)
    • ASCO Annual Meet g Proceed gs Part I [June 20 Supplement]
    • Raman A.K., Lombardo J.C., Chandrasekhar R., Fakih M.G. Bevacizumab related adverse events among various age groups of elderly patients with advanced colorectal cancer (abstract). Journal of Clinical Oncology 2007, 25(18S):14546. ASCO Annual Meeting Proceedings Part I [June 20 Supplement].
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.18 S , pp. 14546
    • Raman, A.K.1    Lombardo, J.C.2    Chandrasekhar, R.3    Fakih, M.G.4
  • 38
    • 33846638744 scopus 로고    scopus 로고
    • Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis
    • February
    • Zhu X., Wu S., Dahut W.L., Parikh C.R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. American Journal of Kidney Diseases 2007, 49(February (2)):186-193.
    • (2007) American Journal of Kidney Diseases , vol.49 , Issue.2 , pp. 186-193
    • Zhu, X.1    Wu, S.2    Dahut, W.L.3    Parikh, C.R.4
  • 39
  • 40
    • 33845760213 scopus 로고    scopus 로고
    • Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease
    • February KDOQI
    • KDOQI Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. American Journal of Kidney Diseases 2007, 49(February (2 Suppl. 2)):S12-S154.
    • (2007) American Journal of Kidney Diseases , vol.49 , Issue.2 SUPPL. 2
  • 41
    • 36849070772 scopus 로고    scopus 로고
    • American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer
    • December
    • Lyman G.H., Khorana A.A., Falanga A., Clarke-Pearson D., Flowers C., Jahanzeb M.W., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. Journal of Clinical Oncology 2007, 25(December (34)):5490-5505.
    • (2007) Journal of Clinical Oncology , vol.25 , Issue.34 , pp. 5490-5505
    • Lyman, G.H.1    Khorana, A.A.2    Falanga, A.3    Clarke-Pearson, D.4    Flowers, C.5    Jahanzeb, M.W.6
  • 42
    • 79955587689 scopus 로고    scopus 로고
    • Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies
    • May
    • Hurwitz H.I., Saltz L.B., Van Cutsem E., et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. Journal of Clinical Oncology 2011, 29(May (13)):1757-1764.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.13 , pp. 1757-1764
    • Hurwitz, H.I.1    Saltz, L.B.2    Van Cutsem, E.3
  • 44
    • 34548141828 scopus 로고    scopus 로고
    • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
    • August
    • Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. Journal of the National Cancer Institute 2007, 99(August (16)):1232-1239.
    • (2007) Journal of the National Cancer Institute , vol.99 , Issue.16 , pp. 1232-1239
    • Scappaticci, F.A.1    Skillings, J.R.2    Holden, S.N.3
  • 45
    • 56349129083 scopus 로고    scopus 로고
    • Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BRITE prospective cohort study (abstract)
    • May Abstr. 4026
    • Kozloff M., Sugrue M., Berlin J., et al. Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: results from the BRITE prospective cohort study (abstract). Journal of Clinical Oncology 2008, May (Suppl.). Abstr. 4026.
    • (2008) Journal of Clinical Oncology , Issue.SUPPL.
    • Kozloff, M.1    Sugrue, M.2    Berlin, J.3
  • 46
    • 0142121282 scopus 로고    scopus 로고
    • Bevacizumab, bleeding, thrombosis, and warfarin
    • September. [3542; author reply]
    • Kilickap S., Abali H., Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. Journal of Clinical Oncology 2003, 21(September (18)):3543. [3542; author reply].
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.18 , pp. 3543
    • Kilickap, S.1    Abali, H.2    Celik, I.3
  • 47
    • 80052210903 scopus 로고    scopus 로고
    • The influence of bevacizumab on platelet function
    • July
    • Fehr M., Catschegn S., Reinhart W.H., et al. The influence of bevacizumab on platelet function. Swiss Medical Weekly 2011, 141(July). 10.4414/smw.2011.13243w13243.
    • (2011) Swiss Medical Weekly , vol.141
    • Fehr, M.1    Catschegn, S.2    Reinhart, W.H.3
  • 48
    • 58749110442 scopus 로고    scopus 로고
    • Incidence of serious bleeding events in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen: results from the BRITE observation cohort study (abstract)
    • May [ASCO annual meet g proceed gs (post-meeting edition)]
    • Flynn P.J., Sugrue M.M., Feng S., et al. Incidence of serious bleeding events in patients with metastatic colorectal cancer receiving bevacizumab as part of a first-line regimen: results from the BRITE observation cohort study (abstract). Journal of Clinical Oncology 2008, 26(May (15S Suppl.)):4104. [ASCO annual meeting proceedings (post-meeting edition)].
    • (2008) Journal of Clinical Oncology , vol.26 , Issue.15 SUPPL. , pp. 4104
    • Flynn, P.J.1    Sugrue, M.M.2    Feng, S.3
  • 49
    • 33645351051 scopus 로고    scopus 로고
    • Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials of bevacizumab with chemotherapy in patients with metastatic colorectal cancer (abstract)
    • [ASCO Annual Meet g Proceed gs]
    • Hambleton J., Skillings J., Kabbinavar F., et al. Safety of low-dose aspirin (ASA) in a pooled analysis of 3 randomized, controlled trials of bevacizumab with chemotherapy in patients with metastatic colorectal cancer (abstract). Journal of Clinical Oncology 2005, 23(June (16S Suppl.)):3554. [ASCO Annual Meeting Proceedings].
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.16 SUPPL. , pp. 3554
    • Hambleton, J.1    Skillings, J.2    Kabbinavar, F.3
  • 50
    • 79960474661 scopus 로고    scopus 로고
    • Safety of bevacizumab in patients with metastatic breast cancer
    • Hamilton E.P., Blackwell K.L. Safety of bevacizumab in patients with metastatic breast cancer. Oncology 2011, 80(5-6):314-325.
    • (2011) Oncology , vol.80 , Issue.5-6 , pp. 314-325
    • Hamilton, E.P.1    Blackwell, K.L.2
  • 51
    • 0034282780 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis
    • September
    • Yano S., Shinohara H., Herbst R.S., et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Research 2000, 60(September (17)):4959-4967.
    • (2000) Cancer Research , vol.60 , Issue.17 , pp. 4959-4967
    • Yano, S.1    Shinohara, H.2    Herbst, R.S.3
  • 52
    • 0035253739 scopus 로고    scopus 로고
    • Safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
    • February
    • Gordon M.S., Margolin K., Talpaz M., et al. safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Journal of Clinical Oncology 2001, 19(February (3)):843-850.
    • (2001) Journal of Clinical Oncology , vol.19 , Issue.3 , pp. 843-850
    • Gordon, M.S.1    Margolin, K.2    Talpaz, M.3
  • 53
    • 67649819585 scopus 로고    scopus 로고
    • Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series
    • May
    • Labidi S.I., Bachelot T., Ray-Coquard I., et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clinical Breast Cancer 2009, 9(May (2)):118-121.
    • (2009) Clinical Breast Cancer , vol.9 , Issue.2 , pp. 118-121
    • Labidi, S.I.1    Bachelot, T.2    Ray-Coquard, I.3
  • 54
    • 70449725036 scopus 로고    scopus 로고
    • Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases
    • November
    • Socinski M.A., Langer C.J., Huang J.E., et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. Journal of Clinical Oncology 2009, 27(November (31)):5255-5261.
    • (2009) Journal of Clinical Oncology , vol.27 , Issue.31 , pp. 5255-5261
    • Socinski, M.A.1    Langer, C.J.2    Huang, J.E.3
  • 56
    • 78449266761 scopus 로고    scopus 로고
    • Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
    • December
    • De Braganca K.C., Janjigian Y.Y., Azzoli C.G., et al. Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal of Neurooncology 2010, 100(December (3)):443-447.
    • (2010) Journal of Neurooncology , vol.100 , Issue.3 , pp. 443-447
    • De Braganca, K.C.1    Janjigian, Y.Y.2    Azzoli, C.G.3
  • 57
    • 77955268612 scopus 로고    scopus 로고
    • Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
    • August
    • Crinò L., Dansin E., Garrido P., et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncology 2010, 11(August (8)):733-740.
    • (2010) Lancet Oncology , vol.11 , Issue.8 , pp. 733-740
    • Crinò, L.1    Dansin, E.2    Garrido, P.3
  • 58
    • 79952027747 scopus 로고    scopus 로고
    • First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients
    • March. ATHENA Study Group
    • Smith I.E., Pierga J.Y., Biganzoli L., ATHENA Study Group, et al. First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Annals of Oncology 2011, 22(March (3)):595-602.
    • (2011) Annals of Oncology , vol.22 , Issue.3 , pp. 595-602
    • Smith, I.E.1    Pierga, J.Y.2    Biganzoli, L.3
  • 59
    • 79952098043 scopus 로고    scopus 로고
    • Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?
    • February
    • Verma N., Swain S.M. Bevacizumab and heart failure risk in patients with breast cancer: a thorn in the side?. Journal of Clinical Oncology 2011, 29(February (6)):603-606.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.6 , pp. 603-606
    • Verma, N.1    Swain, S.M.2
  • 60
    • 79952083872 scopus 로고    scopus 로고
    • Congestive heart failure risk in patients with breast cancer treated with bevacizumab
    • February
    • Choueiri T.K., Mayer E.L., Je Y., et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. Journal of Clinical Oncology 2011, 29(February (6)):632-638.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.6 , pp. 632-638
    • Choueiri, T.K.1    Mayer, E.L.2    Je, Y.3
  • 61
    • 80052709825 scopus 로고    scopus 로고
    • Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib
    • Richards C.J., Je Y., Schutz F.A., et al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. Journal of Clinical Oncology 2011 Sep 1, 29(25):3450-3456.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.25 , pp. 3450-3456
    • Richards, C.J.1    Je, Y.2    Schutz, F.A.3
  • 62
    • 84861963722 scopus 로고    scopus 로고
    • Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib
    • June
    • Pantaleo M.A., Mandrioli A., Saponara M., et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer 2012, 12(June (1)):231.
    • (2012) BMC Cancer , vol.12 , Issue.1 , pp. 231
    • Pantaleo, M.A.1    Mandrioli, A.2    Saponara, M.3
  • 63
    • 34249902080 scopus 로고    scopus 로고
    • First BEAT Investigators. Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: preliminary results from the First BEATrial (abstract 248)
    • Kretzschmar A., Cunningham D., Berry S., et al. First BEAT Investigators. Incidence of gastrointestinal perforations and bleeding in patients starting bevacizumab treatment in first-line mCRC without primary tumour resection: preliminary results from the First BEATrial (abstract 248). Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium 2006.
    • (2006) Paper presented at American Society of Clinical Oncology Gastrointestinal Symposium
    • Kretzschmar, A.1    Cunningham, D.2    Berry, S.3
  • 64
    • 33750344419 scopus 로고    scopus 로고
    • Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy (abstract 3535)
    • [ASCO Annual Meet g Proceed gs Part I]
    • Sugrue M., Kozloff M., Hainsworth J., et al. Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy (abstract 3535). Journal of Clinical Oncology 2006, 24(June (18S Suppl.)):3535. [ASCO Annual Meeting Proceedings Part I].
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.18 SUPPL. , pp. 3535
    • Sugrue, M.1    Kozloff, M.2    Hainsworth, J.3
  • 66
    • 24644454338 scopus 로고    scopus 로고
    • Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab
    • August
    • Ellis L.M., Curley S.A., Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. Journal of Clinical Oncology 2005, 23(August (22)):4853-4855.
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.22 , pp. 4853-4855
    • Ellis, L.M.1    Curley, S.A.2    Grothey, A.3
  • 67
    • 67650137690 scopus 로고    scopus 로고
    • Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer
    • April
    • Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nature Reviews Clinical Oncology 2009, 6(April (4)):207-218.
    • (2009) Nature Reviews Clinical Oncology , vol.6 , Issue.4 , pp. 207-218
    • Eng, C.1
  • 68
    • 64849086646 scopus 로고    scopus 로고
    • Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy
    • May. [quiz 571]
    • Zawacki W.J., Walker T.G., DeVasher E., et al. Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy. Journal of Vascular and Interventional Radiology 2009, 20(May (5)):624-627. [quiz 571].
    • (2009) Journal of Vascular and Interventional Radiology , vol.20 , Issue.5 , pp. 624-627
    • Zawacki, W.J.1    Walker, T.G.2    DeVasher, E.3
  • 69
    • 4644288273 scopus 로고    scopus 로고
    • Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials
    • September
    • Folprecht G., Cunningham D., Ross P., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Annals of Oncology 2004, 15(September (9)):1330-1338.
    • (2004) Annals of Oncology , vol.15 , Issue.9 , pp. 1330-1338
    • Folprecht, G.1    Cunningham, D.2    Ross, P.3
  • 70
    • 41149180580 scopus 로고    scopus 로고
    • Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials
    • March
    • Folprecht G., Seymour M.T., Saltz L., et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. Journal of Clinical Oncology 2008, 26(March (9)):1443-1451.
    • (2008) Journal of Clinical Oncology , vol.26 , Issue.9 , pp. 1443-1451
    • Folprecht, G.1    Seymour, M.T.2    Saltz, L.3
  • 71
    • 33748669385 scopus 로고    scopus 로고
    • Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
    • September
    • Goldberg R.M., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. Journal of Clinical Oncology 2006, 24(September (25)):4085-4091.
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.25 , pp. 4085-4091
    • Goldberg, R.M.1    Tabah-Fisch, I.2    Bleiberg, H.3
  • 72
    • 58249088835 scopus 로고    scopus 로고
    • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials
    • January
    • Kabbinavar F.F., Hurwitz H.I., Yi J., Sarkar S., Rosen O. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. Journal of Clinical Oncology 2009, 27(January (2)):199-205.
    • (2009) Journal of Clinical Oncology , vol.27 , Issue.2 , pp. 199-205
    • Kabbinavar, F.F.1    Hurwitz, H.I.2    Yi, J.3    Sarkar, S.4    Rosen, O.5
  • 74
    • 84861724011 scopus 로고    scopus 로고
    • Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C
    • Price T.J., Zannino D., Wilson K., et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology 2012, 23(6):1531-1536.
    • (2012) Annals of Oncology , vol.23 , Issue.6 , pp. 1531-1536
    • Price, T.J.1    Zannino, D.2    Wilson, K.3
  • 75
    • 77956072936 scopus 로고    scopus 로고
    • Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study
    • Kozloff M.F., Berlin J., Flynn P.J., et al. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. Oncology 2010, 78(5-6):329-339.
    • (2010) Oncology , vol.78 , Issue.5-6 , pp. 329-339
    • Kozloff, M.F.1    Berlin, J.2    Flynn, P.J.3
  • 76
    • 84878577857 scopus 로고    scopus 로고
    • Safety and effectiveness of bevacizumab in combination with chemotherapy in elderly patients with metastatic colorectal cancer: results from a large Czech observational registry
    • Kubala E., Bartos J., Petruzelka L.B., et al. Safety and effectiveness of bevacizumab in combination with chemotherapy in elderly patients with metastatic colorectal cancer: results from a large Czech observational registry. Gastrointestinal Cancers Symposium 2010, 467.
    • (2010) Gastrointestinal Cancers Symposium , pp. 467
    • Kubala, E.1    Bartos, J.2    Petruzelka, L.B.3
  • 77
    • 84875004509 scopus 로고    scopus 로고
    • Effectiveness and safety in very elderly patients treated by bevacizumab plus chemotherapy in first-line therapy of metastatic colorectal cancer: results of ETNA, a French cohort study
    • ETNA Study Group
    • Smith D., Rouyer M., Noize P., ETNA Study Group, et al. Effectiveness and safety in very elderly patients treated by bevacizumab plus chemotherapy in first-line therapy of metastatic colorectal cancer: results of ETNA, a French cohort study. Journal of Clinical Oncology 2011, 29(February (1 Suppl.)):555.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.1 SUPPL. , pp. 555
    • Smith, D.1    Rouyer, M.2    Noize, P.3
  • 78
    • 84860165612 scopus 로고    scopus 로고
    • Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS)
    • May
    • Kozloff M., Bekaii-Saab T.S., Bendell J.C., et al. Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS). Journal of Clinical Oncology 2011, 29(May (20 Suppl.)):3625.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.20 SUPPL. , pp. 3625
    • Kozloff, M.1    Bekaii-Saab, T.S.2    Bendell, J.C.3
  • 79
    • 77952236891 scopus 로고    scopus 로고
    • Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    • May
    • Feliu J., Safont M.J., Salud A., et al. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. British Journal of Cancer 2010, 102(May (10)):1468-1473.
    • (2010) British Journal of Cancer , vol.102 , Issue.10 , pp. 1468-1473
    • Feliu, J.1    Safont, M.J.2    Salud, A.3
  • 80
    • 78650780528 scopus 로고    scopus 로고
    • Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer
    • February
    • Vrdoljak E., Omrčen T., Boban M., Hrabar A. Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer. Anticancer Drugs 2011, 22(February (2)):191-197.
    • (2011) Anticancer Drugs , vol.22 , Issue.2 , pp. 191-197
    • Vrdoljak, E.1    Omrčen, T.2    Boban, M.3    Hrabar, A.4
  • 81
    • 84878535199 scopus 로고    scopus 로고
    • Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab (BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly people
    • May
    • Carreca I.U., Bellomo F., Burgio S.L., Pernice G., Piazza D., Balducci L. Metronomic therapy irinotecan (IRI) capecitabine (CAP) plus bevacizumab (BEV) in treatment of advanced colorectal cancer (ACRC) in very elderly people. Journal of Clinical Oncology 2010, 28(May (20 Suppl.)):3552.
    • (2010) Journal of Clinical Oncology , vol.28 , Issue.20 SUPPL. , pp. 3552
    • Carreca, I.U.1    Bellomo, F.2    Burgio, S.L.3    Pernice, G.4    Piazza, D.5    Balducci, L.6
  • 82
    • 84878593856 scopus 로고    scopus 로고
    • Metronomic (M), capecitabine (C), and oxaliplatin (O) plus bevacizumab (B) as treatment of advanced colorectal cancer (ACRC) in very elderly people (M-COB): Efficacy and safety (E&S) evaluation-a 2-year monitoring
    • Abstr. e14086
    • Carreca I.U., Bellomo F., Pernice G., Antista M., Amelio R., Balducci L. Metronomic (M), capecitabine (C), and oxaliplatin (O) plus bevacizumab (B) as treatment of advanced colorectal cancer (ACRC) in very elderly people (M-COB): Efficacy and safety (E&S) evaluation-a 2-year monitoring. Journal of Clinical Oncology 2011, 29(Suppl.). Abstr. e14086.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.SUPPL.
    • Carreca, I.U.1    Bellomo, F.2    Pernice, G.3    Antista, M.4    Amelio, R.5    Balducci, L.6
  • 83
    • 84878599320 scopus 로고    scopus 로고
    • Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study
    • Abstr. 566
    • Hofheinz R., Grothe W., Tummes D., et al. Bevacizumab in the first-line treatment of elderly patients with metastatic colorectal cancer: Mature results from a large community-based observational study. Journal of Clinical Oncology 2012, 30(Suppl. 4). Abstr. 566.
    • (2012) Journal of Clinical Oncology , vol.30 , Issue.SUPPL. 4
    • Hofheinz, R.1    Grothe, W.2    Tummes, D.3
  • 84
    • 84863115967 scopus 로고    scopus 로고
    • Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients with stage IV colorectal cancer
    • February
    • Meyerhardt J.A., Li L., Sanoff H.K., Carpenter W., Schrag D. Effectiveness of bevacizumab with first-line combination chemotherapy for medicare patients with stage IV colorectal cancer. Journal of Clinical Oncology 2012, 30(February (6)):608-615.
    • (2012) Journal of Clinical Oncology , vol.30 , Issue.6 , pp. 608-615
    • Meyerhardt, J.A.1    Li, L.2    Sanoff, H.K.3    Carpenter, W.4    Schrag, D.5
  • 86
    • 36549075573 scopus 로고    scopus 로고
    • International Society of Geriatric Oncology. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology
    • December
    • Wildiers H., Kunkler I., Biganzoli L., et al. International Society of Geriatric Oncology. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncology 2007, 8(December (12)):1101-1115.
    • (2007) Lancet Oncology , vol.8 , Issue.12 , pp. 1101-1115
    • Wildiers, H.1    Kunkler, I.2    Biganzoli, L.3
  • 87
    • 84155167955 scopus 로고    scopus 로고
    • Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy
    • January
    • Jaggi A.S., Singh N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology 2012, 291(January (1-3)):1-9.
    • (2012) Toxicology , vol.291 , Issue.1-3 , pp. 1-9
    • Jaggi, A.S.1    Singh, N.2
  • 88
    • 77951644093 scopus 로고    scopus 로고
    • Cardiotoxicities of breast cancer treatment
    • [nurse Ed]
    • Viale P.H., Yamamoto D.S. Cardiotoxicities of breast cancer treatment. Oncology (Williston Park) 2009, 23(April (4 Suppl.)):19-24. [nurse Ed].
    • (2009) Oncology (Williston Park) , vol.23 , Issue.4 SUPPL. , pp. 19-24
    • Viale, P.H.1    Yamamoto, D.S.2
  • 89
    • 0345743476 scopus 로고    scopus 로고
    • A comprehensive geriatric intervention detects multiple problems in older breast cancer patients
    • January
    • Extermann M., Meyer J., McGinnis M., et al. A comprehensive geriatric intervention detects multiple problems in older breast cancer patients. Critical Reviews in Oncology Hematology 2004, 49(January (1)):69-75.
    • (2004) Critical Reviews in Oncology Hematology , vol.49 , Issue.1 , pp. 69-75
    • Extermann, M.1    Meyer, J.2    McGinnis, M.3
  • 90
    • 34250010299 scopus 로고    scopus 로고
    • Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy
    • July
    • Hamberg P., Verweij J., Seynaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. European Journal of Cancer 2007, 43(July (10)):1514-1528.
    • (2007) European Journal of Cancer , vol.43 , Issue.10 , pp. 1514-1528
    • Hamberg, P.1    Verweij, J.2    Seynaeve, C.3
  • 91
    • 58049198447 scopus 로고    scopus 로고
    • Chemotherapy and targeted agents for elderly women with advanced breast cancer
    • November
    • Brunello A., Roma A., Falci C., Basso U. Chemotherapy and targeted agents for elderly women with advanced breast cancer. Recent Patents on Anticancer Drug Discovery 2008, 3(November (3)):187-201.
    • (2008) Recent Patents on Anticancer Drug Discovery , vol.3 , Issue.3 , pp. 187-201
    • Brunello, A.1    Roma, A.2    Falci, C.3    Basso, U.4
  • 92
    • 20244368234 scopus 로고    scopus 로고
    • Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women
    • April
    • Bajetta E., Procopio G., Celio L., et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. Journal of Clinical Oncology 2005, 23(April (10)):2155-2161.
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.10 , pp. 2155-2161
    • Bajetta, E.1    Procopio, G.2    Celio, L.3
  • 93
    • 0036225350 scopus 로고    scopus 로고
    • Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
    • January
    • Colleoni M., Rocca A., Sandri M.T., et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Annals of Oncology 2002, 13(January (1)):73-80.
    • (2002) Annals of Oncology , vol.13 , Issue.1 , pp. 73-80
    • Colleoni, M.1    Rocca, A.2    Sandri, M.T.3
  • 94
    • 70349335347 scopus 로고    scopus 로고
    • Management of primary and advanced breast cancer in older unfit patients (medical treatment)
    • October
    • Aapro M., Monfardini S., Jirillo A., Basso U. Management of primary and advanced breast cancer in older unfit patients (medical treatment). Cancer Treatment Reviews 2009, 35(October (6)):503-508.
    • (2009) Cancer Treatment Reviews , vol.35 , Issue.6 , pp. 503-508
    • Aapro, M.1    Monfardini, S.2    Jirillo, A.3    Basso, U.4
  • 95
    • 80052568716 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy in the treatment of HER2- metastatic breast cancer: PFS subgroup results from two phase III studies
    • Glaspy J., Dieras V., Brufsky A., Miles D.W., Phan S.C., O'Shaughnessy J. Bevacizumab in combination with chemotherapy in the treatment of HER2- metastatic breast cancer: PFS subgroup results from two phase III studies. European Journal of Cancer 2010, 8(Suppl.):202.
    • (2010) European Journal of Cancer , vol.8 , Issue.SUPPL. , pp. 202
    • Glaspy, J.1    Dieras, V.2    Brufsky, A.3    Miles, D.W.4    Phan, S.C.5    O'Shaughnessy, J.6
  • 96
    • 84855166988 scopus 로고    scopus 로고
    • Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [meeting abstracts]
    • Abstr. 5016
    • Dieras V., Glaspy J., Brufsky A., et al. Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) [meeting abstracts]. European Journal of Cancer 2009, 7(Suppl.):265. Abstr. 5016.
    • (2009) European Journal of Cancer , vol.7 , Issue.SUPPL. , pp. 265
    • Dieras, V.1    Glaspy, J.2    Brufsky, A.3
  • 97
    • 80054883209 scopus 로고    scopus 로고
    • Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO
    • November
    • Pivot X., Schneeweiss A., Verma S., et al. Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. European Journal of Cancer 2011, 47(November (16)):2387-2395. 10.1016/j.ejca.2011.06.018.
    • (2011) European Journal of Cancer , vol.47 , Issue.16 , pp. 2387-2395
    • Pivot, X.1    Schneeweiss, A.2    Verma, S.3
  • 98
    • 80052428282 scopus 로고    scopus 로고
    • First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study
    • January
    • Biganzoli L., Di Vincenzo E., Jiang Z., et al. First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study. Annals of Oncology 2012, 23(January (1)):111-118.
    • (2012) Annals of Oncology , vol.23 , Issue.1 , pp. 111-118
    • Biganzoli, L.1    Di Vincenzo, E.2    Jiang, Z.3
  • 99
    • 84892625995 scopus 로고    scopus 로고
    • http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4332b1-03-Genentech.pdf.
  • 100
    • 79952602636 scopus 로고    scopus 로고
    • In the end what matters most? A review of clinical endpoints in advanced breast cancer
    • Verma S., McLeod D., Batist G., Robidoux A., Martins I.R., Mackey J.R. In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 2011, 16(1):25-35.
    • (2011) Oncologist , vol.16 , Issue.1 , pp. 25-35
    • Verma, S.1    McLeod, D.2    Batist, G.3    Robidoux, A.4    Martins, I.R.5    Mackey, J.R.6
  • 101
    • 71549143528 scopus 로고    scopus 로고
    • Detecting an overall survival benefit that is derived from progression-free S.
    • Broglio K.R., Berry D.A., Detecting an overall survival benefit that is derived from progression-free survival. Journal of the National Cancer Institute 2009, 101(23):1642-1649.
    • (2009) Journal of the National Cancer Institute , vol.101 , Issue.23 , pp. 1642-1649
    • Broglio, K.R.1    Berry, D.A.2
  • 102
    • 79953874259 scopus 로고    scopus 로고
    • RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
    • April
    • Robert N.J., Diéras V., Glaspy J., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. Journal of Clinical Oncology 2011, 29(April (10)):1252-1260.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.10 , pp. 1252-1260
    • Robert, N.J.1    Diéras, V.2    Glaspy, J.3
  • 103
    • 81155123190 scopus 로고    scopus 로고
    • RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer
    • November
    • Brufsky A.M., Hurvitz S., Perez E., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. Journal of Clinical Oncology 2011, 29(November (32)):4286-4293.
    • (2011) Journal of Clinical Oncology , vol.29 , Issue.32 , pp. 4286-4293
    • Brufsky, A.M.1    Hurvitz, S.2    Perez, E.3
  • 106
    • 84862575323 scopus 로고    scopus 로고
    • Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score
    • July
    • Extermann M., Boler I., Reich R.R., et al. Predicting the risk of chemotherapy toxicity in older patients: the chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 2012, 118(July (13)):3377-3386. 10.1002/cncr.26646.
    • (2012) Cancer , vol.118 , Issue.13 , pp. 3377-3386
    • Extermann, M.1    Boler, I.2    Reich, R.R.3
  • 108
    • 84864285517 scopus 로고    scopus 로고
    • Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
    • June
    • Gnjidic D., Hilmer S.N., Blyth F.M., et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. Journal of Clinical Epidemiology 2012, June.
    • (2012) Journal of Clinical Epidemiology
    • Gnjidic, D.1    Hilmer, S.N.2    Blyth, F.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.